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Abstract
Background: Spinal anaesthesia is the standard of  care for elective caesarean delivery. It has advantages over general anaesthe-
sia. However the sympathetic blockade induced by spinal anaesthesia results in an 80 percent incidence of  hypotension without 
prophylactic management. Current evidence supports co-loading with intravenous fluids in conjunction with the use of  vaso-
pressors as the most effective way to prevent and treat the hypotension. Phenylephrine is the accepted vasopressor of  choice in 
the parturient. A prophylactic phenylephrine infusion combined with a fluid co-load is proven to be an effective and safe method 
of  maintaining maternal hemodynamic stability. While most published studies have assessed the effectiveness of  a prophylactic 
phenylephrine fixed dose infusion, few studies have assessed the effect of  a prophylactic phenylephrine weight adjusted dose 
infusion on maintaining maternal hemodynamic stability following spinal anesthesia for a cesarean delivery.
Objective: To compare the incidence of  hypotension between women undergoing elective caesarean section under spinal an-
aesthesia, receiving prophylactic phenylephrine infusion at a fixed dose of  37.5 micrograms per minute versus a weight adjusted 
dose of  0.5 micrograms per kilogram per minute.
Methods: One hundred and eight patients scheduled for non-urgent caesarean section under spinal anaesthesia were random-
ized into 2 groups; control group and intervention group using a computer generated table of  numbers. 
Control group; Received prophylactic phenylephrine fixed dose infusion at 37.5 micrograms per minute. 
Intervention group; Received prophylactic phenylephrine weight adjusted dose infusion at 0.5 micrograms per kilogram per 
minute
Results: The two groups had similar baseline characteristics in terms of  ; Age, sex, weight and height. There was a 35.2% inci-
dence of  hypotension in the fixed dose group and an 18.6% incidence of  hypotension in the weight adjusted dose group. This 
difference was found to be of  borderline statistical significance p-value 0.05, and the difference in the incidence rates between 
the two groups was found to be statistically significant p= 0.03. The difference in the incidence of  reactive hypertension and 
bradycardia between the two groups was not statistically significant: p-value of  0.19 for reactive hypertension and p-value of  
0.42 for the incidence of  bradycardia. There was also no statistically significant difference in the use of  phenylephrine boluses, 
use of  atropine, intravenous fluid used and the number of  times the infusion was stopped.
Conclusion: Among this population, the incidence of  hypotension was significantly less in the weight adjusted dose group than 
in the fixed dose group. There was no difference in the number of  physician interventions required to keep the blood pressure 
within 20% of  baseline, and no difference in the proportion of  reactive hypertension or bradycardia between the two groups. 
Administering prophylactic phenylephrine infusion at a weight adjusted dose of  0.5 micrograms per kilogram per minute results 
in a lower incidence of  hypotension compared to its administration at a fixed dose of  37.5 micrograms per minute.
Keywords: Weight adjusted dose, fixed dose prophylactic phenylephrine infusion, systolic blood pressure, caesarean section, 
spinal anaesthesia.
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Introduction
Spinal anaesthesia is the preferred mode of  anaesthesia 
for elective caesarean delivery1,2. Benefits include avoid-
ing the risks involved during general anaesthesia such as 
difficult intubation and aspiration of  gastric contents3,4. 
Its use has been associated with reduced maternal mortal-
ity and better neonatal outcomes4.
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Hypotension is the most common complication of  spi-
nal anaesthesia5,6. It may be defined in terms of  a systolic 
blood pressure of  less than 90 or 100mmHg or in rela-
tive terms as a 20% decline of  the systolic blood pressure 
from baseline7.
Consequences of  untreated severe hypotension in the 
mother include: nausea and vomiting, cardiovascular col-
lapse, unconsciousness with resulting pulmonary aspira-
tion, and in extreme cases cardio respiratory arrest and to 
the baby: impaired placental perfusion leading to hypoxia, 
foetal acidosis and  neurological injury8,9.
Measures taken to decrease the risk of  hypotension in-
clude intravenous administration of  fluids either crystal-
loids or colloids5,10,11,12,13, prevention of  aortocaval com-
pression by placing a wedge of  12cm beneath the right 
buttock and use of  vasopressors5,7,8,14.
Ephedrine is an alpha and beta receptor agonist with 
both direct and indirect mechanism of  action, but with a 
slow onset of  action, making it difficult to titrate and use 
with an appropriate bolus dose14.
Studies done have showed that ephedrine crosses the pla-
centa and causes possible alterations in foetal physiology. 
It is also associated with a higher incidence of  nausea and 
vomiting compared to phenylephrine4,15.
Phenylephrine is a short acting alpha agonist, it is a po-
tent vasoconstrictor  that counteracts the vasodilatation 
due to neuraxial anaesthesia and causes an increase in 
both systolic and diastolic blood pressures back to the 
baseline values7. It is widely used as studies done have 
showed better foetal acid base status with reduced inci-
dence of  foetal acidosis as well as lower episodes of  ma-
ternal hypotension with the use of  prophylactic phenyl-
ephrine regimens14,16. Various studies have found reduced 
incidence of  hypotension and intra-operative nausea and 
vomiting when phenylephrine is administered as a pro-
phylactic infusion at various doses  compared with bolus 
administration and other methods, however no infusion 
regimen studied has been found to be more effective than 
others17,18.
Hence, the best phenylephrine dose and mode of  admin-
istration remains undetermined. Previously, studies have 
investigated its use as a prophylactic fixed dose infusion. 
There are no studies that have been done investigating 
how effective a prophylactic weight adjusted dose infu-
sion would be, in terms of  maintaining maternal systol-
ic blood pressure within 20% of  the baseline following 
spinal anaesthesia for caesarean section. Most drugs in 
anaesthesia as well as in medical practice, including va-
sopressors such as phenylephrine are administered at a 
weight adjusted dose as per medical guidelines/recom-
mendations: thus supporting this study’s investigation of  
a weight adjusted dose infusion.
This study was designed to assess how effective phenyl-
ephrine weight adjusted dose infusion regimen would be 
compared to a fixed dose infusion in maintaining mater-
nal systolic blood pressure within 20% of  baseline fol-
lowing spinal anaesthesia given for caesarean section.
Our study question was: does use of  prophylactic phen-
ylephrine weight adjusted dose infusion result in a lower 
incidence of  hypotension following spinal anaesthesia 
given for caesarean delivery compared to its use as a pro-
phylactic fixed dose infusion?
We hypothesised that a weight adjusted dose of  prophy-
lactic phenylephrine infusion results in a lower incidence 
of  hypotension compared to a fixed dose infusion fol-
lowing spinal anaesthesia given for caesarean delivery.
Our primary objective was to compare the incidence of  
hypotension between the two study groups. Our second-
ary objectives were to compare the incidence of  reactive 
hypertension and bradycardia between the two groups 
and establish the number of  physician interventions be-
tween the two study groups.
 
Methods
The study was performed following approval from the 
ethical and scientific review committee at the Aga Khan 
University Hospital, Nairobi. This was a prospective dou-
ble blinded randomized controlled trial; the patient and 
physician administering anaesthesia and collecting data 
were blinded on the nature of  the intervention made.
Since Nairobi is a cosmopolitan city, the patients served 
by this hospital cut across most racial groups present 
within the country. Patients were recruited from the out-
patient pre-anaesthesia clinics and the maternity ward. 
The target population included all patients admitted for 
non-urgent caesarean section at the Aga Khan University 
Hospital, Nairobi. The sample population included 108 
ASA I and II patients going to theatre for non-urgent 
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caesarean section between October 2013 to January 2014. 
This comprised all eligible patients scheduled for non-
urgent caesarean delivery who had given consent for the 
study.
All ASA I and II patients over 18 years scheduled for 
non-urgent caesarean delivery were included in this study. 
Reasons for exclusion from the study were:
1. Patient refusal to participate in the study
2. Patients with contraindications to neuraxial anaesthesia
a. Puncture site infection
b. Hypovolemic shock
c. Coagulopathy
d. Sepsis
e. Features of  raised intracranial pressure
3. Patient involved in any other clinical studies
4. Women scheduled for emergency caesarean section
5. Type 1 Diabetes Mellitus
6. Hypertension
7. Severe cardiac disease graded as New York Heart As-
sociation Class (NYHA) III-IV
 
A sample size of  104 patients was sufficient to demon-
strate a 17% difference in the proportion of  hypotension 
between the two groups at 95% confidence level and a 
power of  80%.
A study done by Allen et al showed the proportion of  
hypotension when a fixed dose of  phenylephrine was 
used at 25µg/min was 30% and 15% when a dose of  
50µg/min was used.17 By using phenylephrine at a dose 
of  37.5µg/min we anticipated an incidence of  20%. Our 
case series using prophylactic phenylephrine at a weight 
adjusted dose of  0.5µg/kg/min resulted in a much re-
duced incidence of  hypotension at 3%.
We therefore hypothesized that there would be a 17% 
less incidence of  hypotension in the weight adjusted dose 
group as compared with the fixed dose infusion. Using 
this information and assuming a 5% significance level and 
a power of  80%, the required sample size was 52 patients 
in each group and a total of  104 patients. We recruited 
108 patients to cater for any data entered wrongly, but all 
data was clearly entered so we analysed all patients.
Patients were recruited after having signed an informed 
consent, which clearly stated that it was a study being 
conducted and that their information would be kept con-
fidential and may be published. Participant flow diagram 
is shown in figure 1. 
No serious adverse event occurred to any patient for the 
entire duration of  the study. The patients were free to 
withdraw from the study at any stage and still be accorded 
standard care.
Simple randomization was done using a computer pro-
gram; the principal investigator generated a random se-
quence of  numbers. Each of  the random numbers was 
sequentially assigned to either;
Group 1; prophylactic phenylephrine fixed dose infusion 
at 37.5 µg /min
Group 2; prophylactic phenylephrine weight adjusted 
dose infusion at 0.5 µg /kg/min.
The study drug was prepared by a physician not involved 
in any other aspect of  the study in identical 20mls syring-
es labelled study drug. This physician held the code for 
randomization and group allocation.  The drug was pre-
sented to the anaesthesiologist and the infusion rate was 
set at 20 mls per hour for both groups. The presentation 
was similar and the only difference was the concentration 
of  the drug in the syringe. The anaesthesiologist was also 
presented with a second 20mls syringe of  phenylephrine 
50µg/ml for bolus phenylephrine administration in case 
systolic blood pressure fell below 20% of  baseline.
On arrival to the operating theatres, standard monitoring 
was applied with automated non-invasive blood pressure 
measurement, electrocardiography and pulse-oximetry: 
with the objective of  obtaining the baseline cardiovascu-
lar parameters. Baseline systolic blood pressure was ob-
tained by taking three readings and calculating an average 
of  the three readings.
After a local infiltration of  2mls 2% Lidocaine solution, 
a midline puncture with a 25 French gauge pencil point 
needle was performed at L3/L4 or L4/ L5 interspace, 
with the patient in the sitting or lateral decubitus posi-
tion. After obtaining free flow of  CSF, 2mls of  bupiva-
caine and 10µg fentanyl were administered. Patients were 
then turned supine with a 15 degree left lateral tilt and 
the study drug together with the fluid co-load at 10mls/
kg were administered over 10 minutes. The study drug 
was run in an infusion pump at 20mls per hour as the 
concentration inside had already been predetermined and 
prepared. The sensory block level to both light touch and 
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temperature was checked and a modified Bromage mo-
tor score recorded. Surgery was allowed to commence as 
soon as the sensory block had reached the desired level. 
NIBP was measured every 2 minutes till delivery of  the 
baby.
Hypotension defined as a reduction in systolic blood 
pressure of  more than 20% from baseline determined 
just before the administration of  regional anaesthesia was 
treated with IV phenylephrine boluses of  50µg. Reactive 
hypertension defined as a rise of  systolic blood pressure 
above 20% of  baseline was treated by stopping the infu-
sion, and restarting it if  blood pressure fell back to base-
line. Bradycardia defined as heart rate less than 60bpm 
was treated by stopping the infusion if  accompanied by 
reactive hypertension or with IV atropine 0.6mg if  ac-
companied by hypotension. The presence of  intraop-
erative nausea and vomiting was also noted and treated 
appropriately; Rescue antiemetic drugs (either IV ondan-
setron 4mg or granisetron 1mg) were to be administered 
at the discretion of  the anaesthesiologist. All the com-
plications that occurred were noted and recorded by the 
anaesthesiologist.
The study drug infusion was discontinued after the deliv-
ery of  the baby. APGAR score was recorded and other-
management thereafter was at the discretion of  the an-
aesthesiologist.
Intraoperative data was collected by the anaesthesiolo-
gist administering anaesthesia or research assistant both 
blinded to patients’ group allocation using the data col-
lection form. Upon collection, data was entered into the 
statistical software (SPSS version 15) on the same day in a 
coded form and saved, awaiting analysis. All data entered 
was verified by the principal investigator. There was no 
missing data and no patient required conversion to gen-
eral anaesthesia.
Analysis was performed using STATA version 12 spe-
cial edition. Descriptive statistics were used to compare 
patients’ characteristics in terms of  age, height, weight, 
baseline blood pressure and heart rates. Students’ T test 
was used to compare if  the 2 sample sizes are statisti-
cally different. The Chi test was used to compare the pro-
portions of  hypotension between the two groups. The 
students’ T test was used to compare the differences be-
tween blood pressure and heart rates reduction between 
the two groups.
Observations (participants) were censored at the first 
event of  interest i.e. hypotension or at the end of  the ob-
servation period (end of  surgery).  Survival time analysis 
(Kaplan Meir) was used to analyse the time to hypoten-
sion. Log rank test was used to compare the rate of  hypo-
tension in the 2 groups.
The incidence rates (IR), and the incidence rate ratio 
(IRR) were reported alongside their corresponding 95% 
CI. Kaplan-Meier survival curves were plotted. The test 
for differences in the survival distributions was conduct-
ed using log rank test.
The differences between the two groups in the total fluids 
given, total phenylephrine boluses and atropine used was 
compared using Mann-Whitney non parametric statistical 
test. All data was presented as mean +/- standard devia-
tion unless otherwise specified. P≤ 0.05 was considered 
statistically significant.
Results
One hundred and eight ASA 1 parturients scheduled to 
undergo non- urgent caesarean section were included in 
this study. Their baseline characteristics are shown in ta-
ble 1.
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Table 2 shows the sensory block achieved before the start of  surgery for the two study groups. 
Table 1: Patients’ baseline characteristics 
  
  Fixed dose group 
n=54 
Mean SD 
Weight adjusted dose group 
n=54 
Mean SD 
P-Value 
Age 
 years 
32.8 4.8 33.5 3.6 0.4 
Weight kg 
  
79.2 11.7 82.9 10.3 0.09 
Height cm 
  
162.5 1.01 162.1 1.09 0.2 
 
                  Data are mean + SD, T-test used to analyse normal distributed variables  
                   and Mann-Whitney U test for skewed data. 
Table 3 shows the primary outcome as the proportion of  hypotension in the two groups. 
Table 2: sensory block level before start of surgery 
  
Sensory  level Fixed dose group 
n % 
Weight adjusted dose group 
n % 
T4                               
   
11% 20% 
T6 
  
79% 66% 
T8 
  
10% 14% 
 
Table 3: Proportion of hypotension between the two groups 
 
  HYPOTENSION     
  No n% 
  
Yes n% Total n% 
Control fixed dose infusion 35 64.8% 
  
19 35.2% 54 100% 
Intervention weight adjusted dose infusion 44 81.4% 
  
10 18.6% 54 100% 
TOTAL 79 73.2% 
  
29 26.8% 108 100% 
P- Value 0.051    
 
(     )
in
(    )
(     ) (     ) (     )
(           ) (           ) (          )
(           ) (           ) (          )
(           ) (           ) (          )
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Table 4 shows the incidence rate of  hypotension during the period of  study for the two study groups. 
The results on presence of  bradycardia, reactive hyper-
tension and number of  physician interventions between 
the control (fixed dose group) and the intervention 
(weight adjusted group) are shown in tables 5, 6 and 7 
respectively.
Table 4: Incidence rate of hypotension between the two groups 
  
  Person time 
minutes 
Hypotensive 
patients n  
Rate 
per 100 person 
minutes 
95% confidence 
intervals 
  
Fixed dose group 
  
636 19 3 1.9 – 4.7 
 Weight adjusted 
dose group 
764 10 1.3 0.7 – 2.4 
Total 
  
1400 29 2.1 1.4 – 3 
Rate Ratio     2.3   
Hazard Ratio 0.43    
P-value 0.035    
 
Table 5: Difference in the rates of reactive hypertension between the fixed dose group and 
the weight adjusted dose group. 
 
Group Proportion 
N % 
Person 
time 
Rate 95% Confidence Interval 
Fixed dose group 18 34% 636 1.6 0.8- 2.9 
Weight adjusted dose 
group 
11 22% 730 0.9 0.4 -1.9 
   P=0.19 
 
 
Table 6: Test for difference in the proportion of bradycardia between the control and the 
intervention arms. 
 
Group Proportion Incidence Rate 95% Confidence Interval 
Fixed dose group 41.5% 4.2 2.7- 6.2 
Weight adjusted dose 
group 
34.0% 3.1 1.9 – 4.8 
P=0.349 
 
 
Table 7: Physician interventions. 
 
  Control: Fixed dose 
Percentage/Mean 
Intervention: weight adjusted dose 
Percentage/Mean 
P- Value 
Infusion stopped 8 15% 5 9% 0.374 
Phenylephrine bolus 17 31% 10 19% 0.119 
Atropine given 7 13% 6 11% 0.73 
Amount of Fluids used 
  
746mls 712mls 0.15 
 
(  )
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The time from induction of  spinal anaesthesia to delivery 
was similar in both groups (range from 15-40 minutes) 
as was the sensory level by cold touch before the start of  
surgery as shown in table 2.
There was 35.2% incidence of  at least one episode of  
hypotension in the control group (Fixed dose group) and 
18.6% in the intervention group (weight adjusted group). 
This difference in the incidence of  hypotension between 
the two groups was found to be of  borderline statistical 
significance (p value of  0.051) as shown in table 3.
The overall total person time minutes to hypotension was 
1400 minutes, with 636 minutes for the control arm and 
764 in the intervention arm. The incidence rate of  hy-
potension in the fixed dose group was 3 per 100 person 
minutes 95% CI 1.9- 4.7 compared to 1.3 per 100 per-
son minutes 95% CI: 0.7- 2.4 in the weight adjusted dose 
group. The rate ratio was 2.3 per 100 person minute the 
patients in the control group had twice the risk of  devel-
oping hypotension compared to those in the intervention 
group and a hazard ratio of  0.43, meaning that patients in 
the intervention arm had 57% chance of  protection from 
hypotension.          
The test for differences in the two incidence rates the test 
of  whether the IRR=1 against that it is different from 1 
was statistically significant, P=0.035. This was a coinci-
dental finding however; as our study was not powered to 
detect this difference.
Based on the lower proportion of  hypotension in the 
weight adjusted dose group compared to the fixed dose 
group table 3 and the much lower incidence rate of  hypo-
tension as illustrated  in table 4, there is good evidence for 
the alternate hypothesis that a weight adjusted infusion 
results in a lower incidence of  hypotension compared to 
a fixed dose infusion.
Figure 2 presents the survival distribution by the treat-
ment group when the event of  interest is hypotension. 
The Log rank test is not significant implying that the two 
survival distributions are not different, P value of  0.06. 
This may be due to the closeness of  the curves in the first 
4 minutes. The curves however, are far from each other 
after 10 minutes. The intervention arm had a higher sur-
vival probability compared to the control arm, implying 
that the intervention arm had a reduced chance of  de-
veloping hypotension after 10 minutes compared to the 
control.
(        ) (       )
(        )
(        )
(        )
(        )
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The rate of  reactive hypertension was calculated for the 
episodes that occurred over the total person time of  ob-
servation. The control arm had an incidence rate of  1.6 
95% CI: 0.8- 2.9 per 100 person minutes while the inter-
vention arm had an incidence rate of  hypertension of  0.9 
95% CI: 0.4- 1.9 per 100 person minutes. The interven-
tion arm had a reduced risk of  hypertension but the test 
for differences in the two incidence rates was not statisti-
cally significant, P=0.19.
The fixed dose arm had an incidence rate of  bradycardia 
of  4.2 95% CI: 2.7, 6.2 per 100 person minutes while the 
weight adjusted dose arm had an incidence rate of  bra-
dycardia of  3.1 95% CI: 1.9, 4.8 per 100 person minutes 
giving an incidence rate ratio IRR of  0.74 95% CI: 0.0.37, 
1.45. This implies that the weight adjusted dose arm had a 
reduced risk of  bradycardia but the test for differences in 
the two incidence rates i.e. the test of  whether the IRR=1 
against that it is different from 1 was not statistically sig-
nificant, P=0.349.
Phenylephrine infusion was stopped in 13  12%  of  all 
the patients, with 8  15%   and 5 9%  in the control and 
intervention arms respectively. The Chi Square test for 
difference in proportions between the two arms Control: 
8  (15%); Intervention: 5 (9%) showed no evidence of  as-
sociation between the control and the intervention arms, 
Chi Square value=0.789 and P=0.374.
(       )
(        )
(      )
Figure1.  Flow diagram of patient distribution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients assessed for 
Eligibility (108) 
Excluded (0) 
Randomized (108) 
Fixed dose 
infusion group 
(54) 
Weight 
adjusted dose 
infusion group 
(54) 
Lost to 
follow up(0) 
Lost to 
follow up 
(0) 
Analyzed (108) 
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Rescue Phenylephrine bolus was given to 27(25%) par-
ticipants. Of  this number, 17(31%) were from the con-
trol arm while 10(19%) were from the intervention arm. 
There was no evidence of  any association between bolus 
and treatment, Chi Square value=2.435, P=0.119.
Similarly, atropine was given to 13(12%) of  the partici-
pants. The proportions of  those who received atropine 
in the control and intervention arms were 6(11%) and 
7(13%0 respectively. The Chi Square test for association 
showed no evidence of  association between the treat-
ment and atropine, Chi Square value=0.111 and P=0.739. 
There was no significant difference in the amount of  in-
travenous fluids Ringer’s Lactate used between the two 
groups p= 0.15
Discussion
To the best of  our knowledge, this is the first study ever 
investigating the use of  prophylactic phenylephrine infu-
sion at a weight adjusted dose in the prevention of  ma-
ternal hypotension following spinal anaesthesia. It is also 
among the first studies investigating use of  prophylactic 
phenylephrine infusion to prevent maternal hypotension 
in our patient population.
The principal finding of  this study was that using a weight 
adjusted dose of  phenylephrine infusion resulted in a 
lower proportion of  hypotension compared to the use 
of  a fixed dose infusion, this difference was of  border-
line statistical significance.  Prophylactic weight adjusted 
dose infusion was also found to significantly reduce the 
incidence rate of  hypotension compared to when a fixed 
dose infusion at 37.5µg/min was used Table 4. 
This study was however not powered to detect a dif-
ference in the incidence rates.  The lower rate of  hypo-
tension in the weight adjusted dose group might be ex-
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plained by the pharmacokinetics of  the drug, different 
doses of  drugs result in different plasma concentration 
of  the drug producing a range of  therapeutic and some 
undesirable responses. Following administration of  a 
drug, its plasma concentration rises to a maximum de-
pending on; its volume of  distribution and the dose that 
has been administered19. Using a standard or a fixed dose 
for all patients fails to account for the wide variation in 
volumes of  distribution20. When a drug is dosed based 
on the patients’ weight the assumption made is that the 
drug pharmacokinetic parameters increase as the body 
size increases20 .This contrasts to using a fixed dose for 
all patients whereby the assumption is that the pharma-
cokinetic parameters remain constant despite changes in 
the body size20.
Phenylephrine is a synthetic, selective, sympathomimetic 
agent alpha 1 agonist. It is usually administered intrave-
nously, it has potent vasoconstrictor properties that oc-
cur almost immediately but only last for 15-20 minutes 
hence it is necessary to administer it as an infusion21. It 
is metabolized in the liver and excreted by the kidneys, 
does not bind to plasma proteins and distributes widely 
throughout the extracellular fluid. Hence administration 
of  phenylephrine in patients with varying weights sug-
gests that weight adjusted phenylephrine dosing may be 
an important consideration. In our study, we used the 
lower limit of  recommended weight adjusted dose of  
phenylephrine at 0.5µg/kg/min, the reason for this was 
to prevent accumulation and toxicity that may occur in 
obese patients. In previous studies done on prophylactic 
phenylephrine infusions the mean weight of  the patients 
studied was 65-70 kegs.
This contrasts to our study whereby the mean weight 
was 85kgs, with a range of  60kgs – 110kgs. This might 
explain why a higher incidence of  hypotension was ob-
served in our patients when the recommended fixed dose 
regimen are used, 35.5% versus 30% reported by Allen 
et al17. James T Miller et al  conducted a retrospective 
cohort study aimed at determining if  the effects of  va-
sopressin on blood pressure and other vasopressor re-
quirement is related to body weight22.They  demonstrated 
that the efficacy of  vasopressin reflected by a decrease in 
other vasopressor requirement is significantly correlated 
to its dose when adjusted for body weight22. Despite the 
fact that this is a different patient population and a dif-
ferent drug, and that this was a retrospective study these 
two drugs are both vasopressors and the findings of  this 
study support weight adjusting the dose of  vasopressors 
to improve their efficacy.
The correct dosing approach can only be known if  drug 
pharmacokinetics are tested across a wide range of  
weights: in our study the range was between 60-110kgs. 
Another assumption made with weight based dosing is 
that; there is a linear relationship between the clearance 
of  a drug and the bodyweight, and that the clearance of  a 
drug increases as the body weight increases20.The findings 
in this trial suggests that in an effort to maintain maternal 
systolic blood pressure as close to the baseline as possible 
using weight adjusted dosing,  prophylactic phenyleph-
rine infusion might offer the advantage of  reducing the 
incidence rate of  hypotension compared to using the in-
fusion as a fixed dose for all patients regardless of  their 
weight. This could be explained by the fact that by weight 
adjusting the dose, we avoid under dosing the drug in 
some patients and increased toxicity in other patients.
In our study, we defined hypotension as a 20% decrease 
in the systolic blood pressure from the baseline. Based 
on a case series of  prophylactic phenylephrine infusion 
at 0.5µg/kg/min, we had postulated that only 3% of  
patients in the weight adjusted group would develop hy-
potension for the entire duration of  the study. The dis-
crepancy between the postulated proportion in the inter-
vention group and the results of  the study was probably 
due to a few methodological flaws in the anecdotal case 
series: no protocol was followed in the administration of  
fluids and the sample size was also very small. Further-
more there is a paucity of  published well designed studies 
that have used weight adjusted prophylactic phenyleph-
rine infusion. The findings of  this study are in keeping 
with our hypothesis; the proportion of  hypotension was 
lower in the intervention arm compared to that in the 
control arm Table 3.
 
The findings in the control group correspond closely 
to the published proportion of  hypotension of  23% by 
Warwick Ngan Kee when he used a fixed dose of  100µg/
min16 and that by Terrence et al who found a propor-
tion of  30% when a fixed dose infusion at 25µg/min was 
used.17
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Reactive hypertension and bradycardia occur frequently 
and are a major concern with the use of  prophylactic 
phenylephrine infusions. Although the differences in the 
incidence rate ratio was not statistically significant, the 
use of  a weight adjusted infusion appeared to reduce the 
risk of  reactive hypertension, Table 5. This can again be 
explained by the fact that by using the weight adjusted 
dose especially in patients at the lower weight range we 
avoided overexposing patients to a higher dose than nec-
essary that would have resulted in reactive hypertension 
and bradycardia. The proportions of  reactive hyperten-
sion in this study closely compare to those reported by 
Allen et al, whereby 25% of  patients developed reactive 
hypertension when a low dose infusion of  25µg/min 
was used and 40% when a dose of  50µg/min was used17. 
The proportion in the weight adjusted group was actually 
much lower than that seen when the low dose infusion 
was used at 25µg/min in an attempt to reduce the pro-
portion of  reactive hypertension.
Phenylephrine infusion is associated with an increase in 
systemic vascular resistance and subsequently causes an 
increase in the blood pressure and a baroreceptor medi-
ated bradycardia. In an editorial Robert A Dyer  suggest-
ed use of  phenylephrine  at low infusion rates to reduce 
hypotension and avoid  reactive hypertension and bra-
dycardia associated with the use of  phenylephrine infu-
sion23. The proportion of  bradycardia shown in Table 6 
was much higher than the proportion observed by Allen 
et al of  15% when a low dose of  25µg/min was used. 
The reason for this is that, in their study bradycardia was 
defined as a heart rate of  less than 50 beats/min unlike in 
our study where we defined it as a heart rate of  less than 
60 beats/min hence the conflicting results17.
 
Our study protocol was to discontinue the infusion when 
baroreceptor mediated bradycardia occurred associated 
with well-maintained blood pressure, rather than the 
administration of  an anticholinergic: hence the num-
ber of  patients who received atropine was much lower 
than those who developed bradycardia. According to this 
work, the best way to reduce hypotension and avoid reac-
tive hypertension and bradycardia is by using a prophylac-
tic phenylephrine infusion at a dose adjusted according to 
the patient’s weight, with supplemental boluses adminis-
tered as necessary.
There was no statistically significant difference between 
the two groups in the amount of  intravenous fluid Ring-
ers lactate used Table 5. Similarly in this study there was 
no difference in the number of  physician interventions 
between the control and the intervention arm in the en-
tire duration of  the study. According to the study pro-
tocol if  the blood pressure dropped below 20% of  the 
baseline a phenylephrine 50µg bolus was given. As seen 
in table 5 more patients in the control arm received phen-
ylephrine bolus 17% versus only 7% in the intervention 
group.  This is due to the fact that the incidence rate of  
hypotension was significantly higher in the control group 
as compared to the intervention group Table 4. Similarly 
the study protocol was to stop the phenylephrine infu-
sion every time the patients’ blood pressure increased 
above 20% of  the baseline. Although the infusion was 
stopped more frequently in the control group than in the 
intervention group this difference was not statistically sig-
nificant. This study was however not adequately powered 
to detect these differences in the secondary outcomes.
No patient required conversion to general anaesthesia in 
this study, and a majority of  patients achieved a sensory 
level of  T6 before surgery began.
Although not reported, we did not see any adverse effects 
on the fetus in our study as indicated by the Apgar score 
that was part of  the data collected. However it is well 
known that any degree of  decrease in maternal cardiac 
output or blood pressure may have detrimental effect on 
the fetus: by causing a reduction in placental blood flow 
and subsequently a reduction in oxygen delivery to the fe-
tus. This is even worse in the emergency situation where 
fetal acidosis may already be present.
In such situations it is important that the anesthesiolo-
gist optimizes oxygen delivery to the fetus by maintain-
ing maternal blood pressure and cardiac output as near 
normal as possible. Hence based on the findings of  this 
study a prophylactic weight adjusted phenylephrine infu-
sion will result in a lower drop in the maternal systolic 
blood pressure and also less bradycardia and less reactive 
hypertension.
 
Strengths of  the study  
After a rigorous literature review, it appears that this is 
the first prospective randomized controlled study that has 
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compared a prophylactic fixed dose infusion to a weight 
adjusted dose infusion. Therefore, this study will add to 
the body of  literature and knowledge on prevention of  
hypotension following spinal anesthesia given for caesar-
ean section and probably form a basis for many other 
studies in the future.
Limitations of  the study   
The study was conducted at a single centre and involved 
a relatively small number of  patients; this may impact on 
the generalizability of  the results of  this study. 
The calculation of  the power of  the current study was 
based on a small number of  anecdotal case series, and 
not a large randomized clinical trial due to paucity of  
published studies on prophylactic phenylephrine weight 
adjusted dose infusion. The case series was retrospective, 
no protocol was involved in the administration of  flu-
ids and vasopressors and the analysis was not rigorous 
enough. This probably explains discrepancy between the 
postulated proportion of  hypotension and the findings 
of  the study 
Conclusion
On the basis of  the results of  this study, patients in the 
weight adjusted dose group had a lower incidence of  hy-
potension compared to those in the fixed dose group. 
This difference was of  borderline statistical significance. 
The difference in heart rate change (bradycardia) between 
the two groups and reactive hypertension was not statisti-
cally significant. Therefore, we conclude that weight ad-
justing the dose of  prophylactic phenylephrine infusion 
at 0.5µg/kg/min results in a lower incidence of  hypo-
tension, slightly lower incidence of  reactive hypertension 
and bradycardia than administering it at a fixed dose of  
37.5µg/min to all patients, regardless of  their weight.
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